PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5 at 10:00 a.m. ET . The Bio-e platform deep dive will provide an overview of the
SOUTH PLAINFIELD, N.J., May 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.. (NASDAQ: PTCT) today announced that it will hold a series of virtual deep dive webinars discussing its therapeutic platforms and programs. The first webinar in the series will discuss its Bio-e platform on Friday, June 5 at 10:00 a.m. ET. The Bio-e platform deep dive will provide an overview of the Bio-e platform and its novel scientific approach to treating central nervous system (CNS) and non-CNS diseases. Bio-e platform technology will be reviewed in detail and prior clinical results for its lead compound PTC743 will be highlighted. Expectations for upcoming trials will be outlined, including potential registrational trials for PTC743 in refractory mitochondrial epilepsy and Friedreich ataxia (FA) and a Phase 1 trial for a second compound, PTC857, targeting GBA Parkinson's disease as its first indication. The webinar can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the webinar and providing the passcode 3978766. A live, listen-only webcast can be accessed on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. A webcast replay will be available approximately two hours after completion of the webinar and will be archived for 30 days following the webinar. About the Bio-e platform About PTC Therapeutics, Inc. For More Information: Investors: Media: Forward-Looking Statements: PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC's products and product candidates; PTC's scientific approach and general development progress; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
SOURCE PTC Therapeutics, Inc. |
||
Company Codes: NASDAQ-NMS:PTCT |